Global Benign Prostatic Hyperplasia Devices Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

Transurethral Resection of the Prostate (TURP) is a well-established surgical procedure that involves the removal of excess prostate tissue obstructing the urethra. TURP is considered a gold standard for treating moderate to severe BPH due to its effectiveness in alleviating symptoms such as urinary frequency, urgency, and hesitancy. This procedure is performed using a resectoscope, which allows urologists to visualize and resect the prostate tissue, providing immediate relief and improving urine flow.

Laser surgeries, including techniques such as GreenLight laser therapy and Holmium laser enucleation of the prostate (HoLEP), offer minimally invasive alternatives to TURP. These procedures utilize laser energy to precisely vaporize or enucleate prostate tissue, reducing obstruction and improving urinary flow. Laser surgeries are preferred for their ability to achieve comparable outcomes to TURP with reduced bleeding, shorter hospital stays, and faster recovery times, making them suitable for patients seeking less invasive treatment options.

Transurethral Microwave Thermotherapy (TUMT) utilizes microwave energy to heat and destroy prostate tissue, alleviating urinary symptoms associated with BPH. This outpatient procedure is performed using a specialized catheter inserted through the urethra, delivering targeted thermal therapy to shrink the prostate gland. TUMT is valued for its minimal discomfort, shorter recovery period, and preservation of sexual function compared to traditional surgical interventions.

Transurethral Needle Ablation (TUNA) employs radiofrequency energy delivered through needles to thermally ablate prostate tissue, reducing obstruction and improving urinary flow. TUNA is performed under local anesthesia and is suitable for patients seeking a minimally invasive outpatient procedure with rapid symptom relief and minimal side effects.

Prostatic stenting involves the placement of small, expandable devices within the prostatic urethra to maintain patency and relieve urinary obstruction caused by BPH. Stents provide mechanical support and allow urine to pass freely through the urethra, offering a temporary solution for patients who may not be suitable candidates for surgical interventions or prefer non-invasive treatment options.

Global Benign Prostatic Hyperplasia Devices Segment Analysis

In this report, the Global Benign Prostatic Hyperplasia Devices Market has been segmented by Procedure, End User and Geography.

Global Benign Prostatic Hyperplasia Devices Market, Segmentation by Procedure

The Global Benign Prostatic Hyperplasia Devices Market has been segmented by Procedure into TURP, Laser surgery, TUMT, TUNA and Prostatic stenting.

Transurethral Resection of the Prostate (TURP) stands as a longstanding and widely used surgical procedure in BPH treatment. TURP involves the removal of excess prostate tissue using a resectoscope inserted through the urethra. This procedure is favored for its efficacy in reducing urinary symptoms such as urgency, frequency, and hesitancy, making it a gold standard for moderate to severe cases of BPH. Despite its effectiveness, TURP requires hospitalization and recovery time, which has led to increased interest in less invasive alternatives.

Laser surgeries, including techniques such as GreenLight laser therapy and Holmium laser enucleation of the prostate (HoLEP), have gained popularity as minimally invasive alternatives to traditional surgical methods like TURP. These procedures use laser energy to precisely vaporize or remove obstructing prostate tissue, offering comparable efficacy with reduced bleeding, shorter hospital stays, and quicker recovery times. Laser surgeries are particularly attractive to patients seeking less invasive treatment options without compromising treatment outcomes.

Transurethral Microwave Thermotherapy (TUMT) utilizes microwave energy delivered through a catheter to heat and destroy prostate tissue obstructing the urethra. TUMT is performed on an outpatient basis and is designed to reduce urinary symptoms associated with BPH while preserving sexual function. This procedure is valued for its minimal discomfort and shorter recovery period compared to surgical interventions, appealing to patients seeking non-invasive treatment options.

Transurethral Needle Ablation (TUNA) involves the insertion of needles emitting radiofrequency energy into the prostate tissue to thermally ablate and shrink enlarged prostate glands. TUNA is performed under local anesthesia and offers a minimally invasive outpatient procedure for symptom relief in BPH patients. It is favored for its rapid recovery and effectiveness in improving urine flow, making it suitable for individuals seeking alternative treatments to surgery.

Prostatic stenting represents a non-surgical approach for managing BPH symptoms by inserting temporary or permanent devices into the prostatic urethra to maintain patency and relieve obstruction. Stents provide mechanical support to facilitate urine flow, offering a temporary solution for patients who are not candidates for surgical interventions or prefer non-invasive treatment options.

Global Benign Prostatic Hyperplasia Devices Market, Segmentation by End User

The Global Benign Prostatic Hyperplasia Devices Market has been segmented by End User into Hospitals and Clinics, Ambulatory Surgical Centres, Others.

The global benign prostatic hyperplasia (BPH) devices market has seen a segmentation based on end users, which plays a significant role in determining the demand for various BPH treatments and devices. Hospitals and clinics are one of the primary end-user segments in the market. These institutions are equipped with advanced medical technologies and skilled healthcare professionals, making them a common choice for patients requiring treatment for BPH. Hospitals, especially larger ones, often have dedicated urology departments capable of performing complex surgeries and offering various BPH treatment options, thus contributing significantly to the market growth.

Ambulatory surgical centers (ASCs) form another important segment in the BPH devices market. ASCs offer patients an alternative to traditional hospital settings for less complex and more cost-effective treatments. With shorter recovery times, lower costs, and reduced waiting periods, ASCs have become increasingly popular for BPH procedures, especially those that do not require overnight stays. The growth in outpatient surgical procedures, coupled with advancements in minimally invasive BPH treatments, is driving the demand for BPH devices in ASCs.

The "Others" segment within the BPH devices market includes a variety of smaller, non-hospital or non-clinic facilities that play a role in BPH treatment. This category may encompass specialized urology centers, private medical practices, and even homecare settings where patients receive follow-up treatments or minor procedures. Though smaller in comparison to hospitals and ASCs, the "Others" segment continues to grow as more healthcare facilities and innovative treatment options become available to meet the increasing demand for BPH care.

Global Benign Prostatic Hyperplasia Devices Market, Segmentation by Geography

In this report, the Global Benign Prostatic Hyperplasia Devices Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Benign Prostatic Hyperplasia Devices Market Share (%), by Geographical Region, 2024

Asia-Pacific represents a rapidly growing market for BPH devices, fueled by increasing healthcare spending, improving healthcare infrastructure, and rising awareness of BPH among aging populations in countries such as China, Japan, and India. The region's large patient pool and expanding access to healthcare services contribute to the demand for both surgical and non-surgical BPH treatments.

Latin America and Middle East & Africa are emerging markets for BPH devices, characterized by improving healthcare access, growing prevalence of BPH, and rising healthcare investments. These regions offer significant opportunities for market growth due to efforts to enhance healthcare infrastructure and address unmet medical needs in BPH management.

The geographical segmentation of the global benign prostatic hyperplasia devices market reflects diverse regional factors influencing market growth and adoption of BPH treatment technologies. While North America and Europe lead in technological advancements and healthcare expenditure, Asia-Pacific, Latin America, and the Middle East & Africa present opportunities for market expansion driven by demographic trends, increasing healthcare investments, and evolving healthcare policies. As healthcare systems worldwide continue to evolve, the global BPH devices market is expected to witness continued growth, driven by innovation in medical technologies and personalized approaches to improving patient outcomes in BPH management.

This report provides an in depth analysis of various factors that impact the dynamics of Global Benign Prostatic Hyperplasia Devices Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Aging population
• Increasing prevalence of BPH
• Technological advancements in medical devices

• Minimally invasive procedures - Patient reluctance towards surgical interventions for benign prostatic hyperplasia (BPH) stems from several factors that impact treatment decision-making and patient outcomes. Surgical procedures like Transurethral Resection of the Prostate (TURP) or open prostatectomy are effective in alleviating symptoms but are associated with perceived risks, recovery challenges, and potential impacts on quality of life.

  One significant concern for patients considering surgical interventions is the risk of complications. Although modern surgical techniques have significantly reduced the incidence of complications such as bleeding, infection, and urinary incontinence, these risks can still deter patients, especially those with underlying health conditions or advanced age.

  Recovery time and post-operative discomfort are also critical factors contributing to patient reluctance. Traditional surgical procedures often require hospitalization and entail a longer recovery period compared to minimally invasive techniques. Patients may anticipate prolonged catheterization, temporary urinary symptoms, and restrictions on daily activities, impacting their overall quality of life during the recovery phase.

  Long-term implications such as potential impact on sexual function, urinary continence, and overall prostate health are also considerations for patients weighing surgical options. While surgical interventions aim to improve urinary symptoms and quality of life, patients may worry about the permanence of outcomes and the need for ongoing management or additional procedures in the future.

  To address patient reluctance towards surgical interventions, healthcare providers play a crucial role in providing comprehensive education and counseling. Explaining the benefits, risks, and expected outcomes of surgical procedures in a clear and empathetic manner can help alleviate fears and empower patients to make informed decisions. Additionally, discussing alternative treatments such as minimally invasive procedures, medications, or lifestyle modifications provides patients with a range of options aligned with their preferences and health goals.

Restraints:

• High treatment costs
• Limited access to advanced medical facilities
• Regulatory challenges and approval processes

• Patient reluctance towards surgical interventions - Patient reluctance towards surgical interventions for benign prostatic hyperplasia (BPH) can be attributed to several key factors that influence treatment decision-making and patient preferences. These factors include.

  Surgical procedures like Transurethral Resection of the Prostate (TURP) or open prostatectomy carry inherent risks, including bleeding, infection, and potential complications related to anesthesia. Patients may be apprehensive about these risks, especially those with existing health conditions or concerns about surgical outcomes impacting their overall health.

  The recovery period following surgical interventions for BPH can be lengthy and may involve discomfort, pain, and temporary lifestyle changes such as catheterization or restricted physical activity. Patients may be reluctant to undergo procedures that require hospitalization and extended recovery times, impacting their daily routines and quality of life during the post-operative phase.

  Surgical interventions for BPH, while effective in relieving urinary symptoms, can potentially affect sexual function and urinary continence. Concerns about long-term implications on sexual health or the potential need for additional treatments may deter patients from opting for surgical procedures, particularly those who prioritize preserving their sexual function.

  The availability of non-surgical alternatives such as medications, minimally invasive procedures (e.g., laser therapy, prostate artery embolization), and lifestyle modifications provides patients with viable options to manage BPH symptoms without undergoing surgery. Patients may prefer less invasive treatments that offer similar efficacy in symptom relief while minimizing procedural risks and recovery challenges.

Opportunities:

• Expansion into emerging markets
• Development of innovative and cost-effective treatments
• Increasing adoption of minimally invasive procedures

• Rising healthcare awareness and patient education - Rising healthcare awareness and patient education play crucial roles in transforming healthcare dynamics, particularly in the context of benign prostatic hyperplasia (BPH) and its management. As awareness increases and education improves, several significant benefits emerge that positively impact patient outcomes and healthcare systems.

  Increased awareness encourages individuals to recognize symptoms of BPH early, prompting them to seek medical advice and undergo screening tests. Early detection enables timely intervention and treatment, potentially preventing complications and improving long-term prognosis.

  Educated patients have a better understanding of available treatment options for BPH, including surgical and non-surgical interventions, medications, and lifestyle modifications. This knowledge empowers patients to actively participate in shared decision-making with healthcare providers, choosing treatment plans aligned with their preferences, values, and health goals.

  Patient education fosters understanding of treatment goals, potential benefits, and expected outcomes, which enhances treatment adherence. Educated patients are more likely to comply with prescribed medications, follow recommended lifestyle changes, and attend follow-up appointments, optimizing the effectiveness of BPH management strategies.

  Enhanced awareness contributes to debunking myths and reducing stigma associated with BPH and related conditions. Open discussions about symptoms, treatment options, and potential impacts on quality of life help normalize conversations about men's health issues, encouraging more individuals to seek timely medical care without hesitation.

  Healthcare awareness campaigns emphasize preventive health measures such as regular health screenings, healthy lifestyle choices (e.g., diet, exercise), and proactive management of chronic conditions like BPH. By promoting preventive practices, awareness initiatives aim to reduce disease burden, improve overall health outcomes, and alleviate strain on healthcare systems.

Key players in Global Benign Prostatic Hyperplasia Devices Market include:

• Olympus
• Lumenis
• Karl Storz

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis